Successful Exit: BayBG Sells Its Stake in Specialty Pharma Company AMW

Ren Life Sciences and Juno Capital Partners Become New Majority Shareholders

Munich, March 5, 2026 – BayBG has sold its stake in AMW GmbH, a specialty pharmaceutical company focused on biodegradable systems for controlled drug delivery, to the investment firms Ren Life Sciences and Juno Capital Partners. BayBG had been invested in AMW since 2014.

AMW specializes in biodegradable implants and provides patients and partners with access to innovative medicines. The company’s goal is to improve therapy adherence while supporting cost-efficient treatments. AMW covers the entire value chain, from (co-)development and manufacturing to international commercialization.

BayBG recognized AMW’s potential at an early stage and played a key role in driving the company’s development as an investor. “We have closely supported AMW throughout its growth journey,” explains Dr. Marcus Gulder, Head of BayBG Venture Capital. “AMW is an excellent example of how a startup can evolve into a sustainably competitive life sciences company based on strong technological expertise and high innovative strength. We wish Philipp Karbach and his team continued success in the next phase of growth.”

Ren Life Sciences, a European investment firm specialized in supporting life sciences companies, and Juno Capital Partners, a global pharmaceutical-focused investment firm headquartered in Toronto, Canada, are acquiring the shares in AMW GmbH from the existing shareholders BayBG, Bayern Kapital, KfW, UVC Partners and bmp Ventures (with the IBG funds) and will become the new majority owners of the company.

Two existing shareholders will remain invested: SHS Capital, a specialist investor in fast-growing European healthcare companies and the first investor in AMW GmbH, and AMW Evolution, a special purpose vehicle representing the chairman of the advisory board, the management team and employees of the company.